Therapy in poisonings--antidote 7: the antidotes physostigmine salicylate, toluidin blue
Daunderer, M.
Fortschritte der Medizin 98(7): 245-248
1980
ISSN/ISBN: 0015-8178 PMID: 7364382 Document Number: 162906
Document emailed within 1 workday
Related Documents
Daunderer, M. 1978: Therapy for poisonings--antidotes. 1. the ABC of poisoning treatment, antidotes (indications, dosage) Fortschritte der Medizin 96(25): 1313-1317Navrátil, J.; Sklenovský, A.; Chmela, Z.; Rypka, M. 1989: Perspectives of physostigmine as antidote by toluene intoxication Acta Universitatis Palackianae Olomucensis Facultatis Medicae 121: 267-270
Walter, K.; Aschoff, J.C. 1996: Physostigmine. from the God's judgment bean to modern antidote and therapeutic agent Medizinische Monatsschrift für Pharmazeuten 19(9): 252-260
Trose, D.; Slowig, P. 1985: Stabilization of physostigmine salicylate injection solutions Die Pharmazie 40(2): 124-126
Yang, S.T.; Wilken, L.O. 1988: The effects of autoclaving on the stability of physostigmine salicylate in buffer solutions Journal of Parenteral Science and Technology: a Publication of the Parenteral Drug Association 42(2): 62-67
Rygnestad, T. 1992: Development of physostigmine from a poisonous plant to an antidote. one of the most important drugs in the development of modern medicine? Tidsskrift for den Norske Laegeforening: Tidsskrift for Praktisk Medicin Ny Raekke 112(10): 1300-1303
Korte, D.W.; Frost, D.F.; Zaucha, G.M.; Waring, P.P.; Clifford, C.B.; Wheeler, C.R. 1989: 28-day toxicity in beagle dogs of physostigmine salicylate administered via subcutaneously implanted Alzet osmotic minipumps Proceedings of the Western Pharmacology Society 32: 159
Pupo, Y.M.; Gomes, G.M.; Santos, E.B.; Chaves, L.; Michel, M.D.; Kozlowski, V.A.; Gomes, O.M.M.; Gomes, J.ãd.C. 2011: Susceptibility of Candida albicans to photodynamic therapy using methylene blue and toluidine blue as photosensitizing dyes Acta Odontologica Latinoamericana: Aol 24(2): 188-192
Knapp, S.; Wardlow, M.L.; Albert, K.; Waters, D.; Thal, L.J. 1991: Correlation between plasma physostigmine concentrations and percentage of acetylcholinesterase inhibition over time after controlled release of physostigmine in volunteer subjects Drug Metabolism and Disposition: the Biological Fate of Chemicals 19(2): 400-404
Horn, J. 1995: Acute poisoning. 4: Antidote therapy Fortschritte der Medizin 113(12): 178-180
Boiarintsev, V.V.; Grebeniuk, A.N.; Minaev, D.I.; Nazarov, V.B. 2008: Antidote therapy for cyanide poisoning Voenno-Meditsinskii Zhurnal 329(5): 16-19
Shabalina, L.P.; Krillov, V.F.; Spiridonova, V.S.; Poliakova, M.M.; Popova, O.L.; Shamshinova, A.M. 1996: Methods of diagnosis of thallium intoxication and its antidote therapy Meditsina Truda i Promyshlennaia Ekologiia 10: 25-30
Novikov, S.M.; Melńikova, N.N.; Neriueva, V.V.; Semenovykh, L.N.; Murkova, M.V. 1994: Hygienic standardization of methyl salicylate and isoamyl salicylate in the atmospheric air of populated areas Gigiena i Sanitariia 1: 4-5
Brick, D.L.; Corrigan, A.B. 1970: Plasma salicylate levels in rheumatoid arthritis produced by four different salicylate preparations Medical Journal of Australia 2(8): 382-383
Ackerman, M.J. 2013: Computer briefs: Blue Cross, Blue Shield, Blue Button Journal of Medical Practice Management: Mpm 28(6): 394-395
Hill, J.B. 1971: Experimental salicylate poisoning: observations on the effects of altering blood pH on tissue and plasma salicylate concentrations Pediatrics 47(4): 658-665
Wellhöner, H.H. 1981: Specific therapy in poisonings Medizinische Monatsschrift für Pharmazeuten 4(6): 166-173
Pollmann, H.; Zillessen, E. 1992: Endoscopic therapy following oral poisonings Deutsche Medizinische Wochenschrift 117(16): 643
Iufa, E.I. 1984: Emergency therapy of poisonings in children Fel'dsher i Akusherka 49(12): 21-26
Moshkin, E.A.; Pukach, L.P. 1973: Gastric lavage in the therapy of chlorophos poisonings Voenno-Meditsinskii Zhurnal 3: 42-44